Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents

References

• O'Brien SG, Guilhot F, Larson RA, et al Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Deininger M, O'Brien SG, Guilhot F, et al International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): 462 (Abstract 1126).
   Google Scholar
• Baccarani M, Cortes J, Pane F, et al Chronic myeloid leukemia: an update of concepts and management recommendations of european LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Goldman JM, et al International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112(Suppl. 1): 76 (Abstract 186).
   Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, et al Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, et al Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–916.
   PubMed Web of Science ®Google Scholar
• Wolf A, Couttet P, Dong M, et al Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 2010 Jan 30. [Epub ahead of print].
   Web of Science ®Google Scholar
• Hatfield A, Owen S, Pilot PR. In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med 2007;13:13, author reply 15–16.
   PubMed Web of Science ®Google Scholar
• Rosti G, Martinelli G, Baccaran M. In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med 2007;13:15, author reply 15–16.
   PubMed Web of Science ®Google Scholar
• Atallah E, Kantarjian H, Cortes J. In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med 2007;13:14, author reply 15–16.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to ‘cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med 2007;13:13–14, author reply 15–16.
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233–1237.
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F, et al Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114:4933–4938.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, et al Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392–397.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, et al Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial. Blood 2009;114(Suppl. 1): (Abstract LBA-1).
   Google Scholar
• Cortes JE, Jones D, O'Brien S, et al Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398–404.
   PubMed Web of Science ®Google Scholar
• Redaelli S, Piazza R, Rostagno R, et al Activity of bosutinib, dasatinib, and nilotnib against 18 imatinib-resistant BCR-ABL mutants. J Clin Oncol 2009;27:469–471.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian HM, Kim DW, et al Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood 2008;112(Suppl. 1): (Abstract 1098).
   Google Scholar
• Marin D, Maloisel F, Legros L, Nicolini FE, Roy L, Rousselot P. Efficacy of subcutaneous homoharringtonine in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors and harboring a BCR-ABL mutation. Haematologica 2008;93(Suppl. 1): 56 (Abstract 0139).
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248–255.
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Khoury HJ, Nicolini FE, et al Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the bcr-abl T315I mutation – results of an ongoing multicenter phase 2/3 study. Blood 2009;114(Suppl. 1): 267 (Abstract 644).
   Google Scholar
• Cortes-Franco J, Raghunadharao D, Rarikh P, et al Safety and efficacy of subcutaneous-administered omaxetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors – results of a multicenter phase 2/3 study. Blood 2009;114:354–355.
   Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, et al Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204–4210.
   PubMed Web of Science ®Google Scholar
• Tasigna (nilotinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
   Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Melnick JS, Janes J, Kim S, et al An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006;103:3153–3158.
   PubMed Web of Science ®Google Scholar
• Das J, Chen P, Norris D, et al 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)- 2-[[6-[4-(2-hydroxyethyl)- 1-piperazinyl)]- 2-methyl-4-pyrimidinyl]amino)]- 1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49:6819–6832.
   PubMed Web of Science ®Google Scholar
• Das J, Patmanabha R, Chen P, Norris DJ, Doweyko AMP, Barrish JC. Cyclic protein tyrosine kinase inhibitors. US patent 6979694, 27 December 2005.
   Google Scholar
• Muller MC, Cortes JE, Kim DW, et al Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944–4953.
   PubMed Web of Science ®Google Scholar
• Sprycel (dasatinib) [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2009.
   Google Scholar
• Bradeen HA, Eide CA, O'Hare T, et al Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332–2338.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Hochhaus A, Cortes J, La Rosee P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010;24:6–12.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V, et al Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136–4147.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, et al Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200–1206.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009;114(Suppl. 1): 464 (Abstract 1129).
   Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
   PubMed Web of Science ®Google Scholar
• Carpiuc KT, Stephens JM, Liou SY, Botteman MF. Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib. J Clin Oncol 2007;25:680s.
   Google Scholar
• Nicolini F, Alimena G, Al-Ali HK, et al Final safety analysis of 1,793 CML patients from ENACT (expanding nilotinib access in clinical trials) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML). Haematologica 2009;94:255–256.
   Web of Science ®Google Scholar
• Nicolini FE, Kim D-W, Ceglarek B, et al Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood 2009;114(Suppl. 1): 866 (Abstract 2201).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian H, Baccarani M, et al Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP). Hematologica 2008;93:56–57.
   Web of Science ®Google Scholar
• Jabbour E, Hochhaus A, le Coutre P, et al Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). J Clin Oncol 2008;26:387s.
   Google Scholar
• Cortes J, O'Brien S, Jones D, et al Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 2009;114(Suppl. 1): 144 (Abstract 338).
   Google Scholar
• O'Dwyer MC, Kent E, Parker M, et al Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study. Blood 2009;114(Suppl. 1): 1277 (Abstract 3294).
   Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Goldberg SL, Mauro MJ, et al Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol 2008;26:375s.
   Google Scholar
• Guilhot F, Goldberg SL, Stone RM, et al Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) who are intolerant to imatinib – a retrospective safety analysis. Haematologica 2008;93(Suppl. 1): 51 (Abstract 0128).
   Google Scholar
• Shah NP. Bench to bedside: BRCA: from therapeutic target to therapeutic shield. Nat Med 2008;14:495–496.
   PubMed Web of Science ®Google Scholar
• Gleevec (imatinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
   Google Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, et al Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–2309.
   PubMed Web of Science ®Google Scholar
• Bergeron A, Rea D, Levy V, et al Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814–818.
   PubMed Web of Science ®Google Scholar
• Masiello D, Gorospe G III, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic myelogenous leukemia. Version 2. 2010. Available from: http://www.nccn.org.
   Google Scholar
• Quintas-Cardama A, Kantarjian HM, O'Brien S, et al Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. Blood 2008;112(Suppl. 1): 735 (Abstract 2112).
   Google Scholar
• Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007;97:247–274.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al Discovery of N-(2-chloro-6-methyl- phenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)- 2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Lee F, Lombardo LJ, Camuso A. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005;46: Abstract 675.
   Google Scholar
• Luton F, Verges M, Vaerman JP, Sudol M, Mostov KE. The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 1999;4:627–632.
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by src family kinases. Annu Rev Cell Dev Biol 1997;13:513–609.
   PubMed Web of Science ®Google Scholar
• Carragher NO, Westhoff MA, Fincham VJ, Schaller MD, Frame MC. A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and src. Curr Biol 2003;13:1442–1450.
   PubMed Web of Science ®Google Scholar
• Carragher NO, Frame MC. Calpain: a role in cell transformation and migration. Int J Biochem Cell Biol 2002;34:1539–1543.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H, Baccarani M. A phase 1/2 study of SKI-606, a dual inhibitor of src and abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia relapsed, refractory or intolerant of imatinib. Blood 2006;108(Suppl. 1): (Abstract 168).
   Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314–11322.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Dasatinib (BMS-35825) oncologic drug advisory committee briefing document NDA 21–96. Washington, DC: US FDA; 2006. p. 52.
   Google Scholar
• Mauro MJ, Baccarani M, Cervantes F, et al Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26:374s.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Ravandi F. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Blood 2007;110(Suppl. 1): 869a (Abstract 2598).
   Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–3546.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261–263.
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Martin V, Valera MC, et al The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884–1892.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Ottmann OG, Giles F, et al Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834–1839.
   PubMed Web of Science ®Google Scholar
• Hazarika M, Jiang X, Liu Q, et al Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14:5325–5331.
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Soverini S, et al Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica 2009;94:1758–1761.
   PubMed Web of Science ®Google Scholar
• Lang E, Afilalo M, Dankoff J, Colacone A, Tselios C, Guttman A. The prognostic significance of moderate hyperamylasemia in the evaluation of the emergency department patient. J Emerg Med 1995;13:107–112.
   PubMedGoogle Scholar
• Frulloni L, Patrizi F, Bernardoni L, Cavallini G. Pancreatic hyperenzymemia: clinical significance and diagnostic approach. JOP 2005;6:536–551.
   PubMedGoogle Scholar
• Gullo L. Benign pancreatic hyperenzymemia. Dig Liver Dis 2007;39:698–702.
   PubMedGoogle Scholar
• Rosti G, Castagnetti F, Palandri F, et al Nilotinib 800 mg daily as frontline therapy of Ph + chronic myeloid leukemia: dose delivered and safety profile for the GIMEMA CML working party. Blood 2009;114(Suppl. 1): 868 (Abstract 2205).
   Google Scholar
• Singer JB, Shou Y, Giles F, et al UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311–2315.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Giles FJ, Hochhaus A, et al Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients (pts) treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy. Blood 2007;110(Suppl. 1): (Abstract 4588).
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, et al Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007;31:1770–1772.
   PubMed Web of Science ®Google Scholar
• Cheng H, Straub SG, Sharp GW. Inhibitory role of src family tyrosine kinases on Ca2+-dependent insulin release. Am J Physiol Endocrinol Metab 2007;292:E845–E852.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001;6:233–238.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:409–429.
   PubMed Web of Science ®Google Scholar
• Marin D, Marktel S, Bua M, et al Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003;17:1448–1453.
   PubMed Web of Science ®Google Scholar
• Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000;254:1–13.
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 1992;89:1710–1714.
   PubMed Web of Science ®Google Scholar
• Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037–1051.
   PubMed Web of Science ®Google Scholar
• Rossi AR, Ricco A, Carluccio P, et al T/NK lymphocytosis in CML Ph+ patients during dasatinib therapy. Blood 2009;114(Suppl. 1): (Abstract 3279).
   Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, et al Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398–1405.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kamel-Reid S, Chang H, et al Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135–139.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes J, Kantarijian H, et al Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with Philadelphia chromosome positive leukemias. Haematologica 2008;93:160–161.
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Baccarani M, et al Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J Clin Oncol 2008;26:7049.
   Google Scholar
• Bruemmendorf TH, Cervantes F, Kim D, et al Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 2008;26:7001.
   Google Scholar
• Cooper S, Giles FJ, Savona MR. Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma 2009;50:1785–1793.
   PubMed Web of Science ®Google Scholar
• Modugno M, Casale E, Soncini C, et al Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987–7990.
   PubMed Web of Science ®Google Scholar
• Gontarewicz A, Balabanov S, Keller G, et al Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008;111:4355–4364.
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Dombret H, Schafhausen P, et al Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009;114(Suppl. 1): (Abstract 864).
   Google Scholar
• Sillaber C, Herrmann H, Bennett K, et al Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009;39:1098–1099.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F, et al Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424–430.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–356.
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477–485.
   PubMed Web of Science ®Google Scholar
• Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005;1754:3–13.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Akin C, Manshouri T, et al Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006;30:1365–1370.
   PubMed Web of Science ®Google Scholar